B. Riley Wealth Advisors Inc. Buys New Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

B. Riley Wealth Advisors Inc. purchased a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 11,435 shares of the company’s stock, valued at approximately $163,000.

A number of other hedge funds and other institutional investors have also modified their holdings of TAK. Wilmington Savings Fund Society FSB purchased a new position in shares of Takeda Pharmaceutical during the third quarter valued at approximately $40,000. EverSource Wealth Advisors LLC lifted its stake in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares during the last quarter. Smithfield Trust Co boosted its holdings in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Takeda Pharmaceutical in the third quarter valued at $52,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $13.10 on Monday. The business’s 50-day moving average price is $13.70 and its 200 day moving average price is $13.88. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08. The company has a market capitalization of $41.68 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.